3.17
Evolent Health Inc stock is traded at $3.17, with a volume of 2.38M.
It is down -6.76% in the last 24 hours and up +11.23% over the past month.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
See More
Previous Close:
$3.40
Open:
$3.39
24h Volume:
2.38M
Relative Volume:
0.74
Market Cap:
$353.89M
Revenue:
$2.05B
Net Income/Loss:
$-128.18M
P/E Ratio:
-2.0196
EPS:
-1.5696
Net Cash Flow:
$-68.67M
1W Performance:
-2.46%
1M Performance:
+11.23%
6M Performance:
-67.01%
1Y Performance:
-65.95%
Evolent Health Inc Stock (EVH) Company Profile
Name
Evolent Health Inc
Sector
Industry
Phone
571-389-6000
Address
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Compare EVH vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
EVH
Evolent Health Inc
|
3.17 | 379.57M | 2.05B | -128.18M | -68.67M | -1.5696 |
|
VEEV
Veeva Systems Inc
|
195.49 | 32.23B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
52.26 | 9.48B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.49 | 8.08B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
78.36 | 6.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
25.71 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-13-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jan-10-25 | Initiated | Needham | Buy |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Nov-08-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-09-24 | Upgrade | Truist | Hold → Buy |
| Apr-22-24 | Initiated | Citigroup | Buy |
| Mar-01-24 | Initiated | Oppenheimer | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-23 | Initiated | UBS | Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Nov-01-22 | Initiated | Truist | Hold |
| Jul-29-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Nov-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-29-21 | Resumed | JP Morgan | Neutral |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Jul-06-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-05-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-05-18 | Resumed | Leerink Partners | Outperform |
| Jun-04-18 | Initiated | Piper Jaffray | Overweight |
| Apr-24-18 | Resumed | JP Morgan | Neutral |
| Sep-20-17 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-02-17 | Initiated | Robert W. Baird | Outperform |
| Mar-14-17 | Initiated | Oppenheimer | Outperform |
| Jan-13-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Oct-28-16 | Resumed | JP Morgan | Overweight |
| Aug-05-16 | Reiterated | FBR Capital | Outperform |
| Jul-26-16 | Initiated | Jefferies | Buy |
| Jul-13-16 | Reiterated | FBR Capital | Outperform |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Jan-06-16 | Initiated | Canaccord Genuity | Buy |
| Jun-30-15 | Initiated | Goldman | Buy |
| Jun-30-15 | Initiated | JP Morgan | Overweight |
| Jun-30-15 | Initiated | Leerink Partners | Outperform |
| Jun-30-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Evolent Health Inc Stock (EVH) Latest News
How Evolent Health Inc Class stock expands through international markets2026 Macro Impact & Verified Trade Idea Suggestions - Naître et grandir
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones - Stock Traders Daily
How The Evolent Health (EVH) Investment Story Is Shifting After Reserves Reset And Higher Leverage - Yahoo Finance
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Profit Recap: Is Madison Square Garden Entertainment Corp stock influenced by commodity pricesWeekly Trend Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Evolent Health (EVH) CFO awarded 429,041 performance share units tied to 2027–2029 stock goals - Stock Titan
EVH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Cowen Maintains Buy on Evolent Health (EVH) March 2026, PT Cut to $7 - Meyka
TD Cowen cuts Evolent Health stock price target to $7 on 2026 outlook - Investing.com Canada
Oppenheimer Cuts Evolent Health (NYSE:EVH) Price Target to $6.00 - MarketBeat
Evolent Health (EVH) Receives Updated Analyst Rating from Oppenh - GuruFocus
Oppenheimer Adjusts Evolent Health Price Target to $6 From $12, Maintains Outperform Rating - marketscreener.com
Evolent Health Charts Growth Amid 2026 Margin Squeeze - TipRanks
Privia Health Expands Value Based Care Scale With Evolent ACO Acquisition - Yahoo Finance
Wall Street Zen Upgrades Evolent Health Stock Rating - National Today
Evolent Health (NYSE:EVH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Evolent Health and iRhythm Shares Are Falling, What You Need To Know - Yahoo Finance
EVH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Evolent Health Inc affected by consumer sentimentTrade Risk Assessment & Risk Managed Investment Signals - baoquankhu1.vn
Evolent to Participate in Upcoming Investor Conferences - The Malaysian Reserve
Evolent Health price target lowered to $4 by Citigroup - National Today
EVH: Citigroup Maintains Buy Rating, Lowers Price Target | EVH S - GuruFocus
Evolent Health downgraded at KeyBanc on EBITDA recovery concerns - MSN
Hear Evolent execs at March Cowen and Oppenheimer investor conferences - Stock Titan
Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Citigroup - MarketBeat
UBS Maintains Evolent Health (EVH) Rating, Lowers Price Target | - GuruFocus
UBS Group Lowers Evolent Health (NYSE:EVH) Price Target to $5.00 - MarketBeat
Privia Health Group, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Evolent Health: Cheap, Levered, But Ready To Rebound (NYSE:EVH) - Seeking Alpha
UBS Adjusts Evolent Health Price Target to $5 From $10, Maintains Buy Rating - marketscreener.com
Truist Cuts Price Target on Evolent Health to $6 From $10, Keeps Buy Rating - marketscreener.com
Privia Health (PRVA) Q4 2025 Earnings Transcript - AOL.com
Evolent Health, Inc. (NYSE:EVH) Q4 2025 Earnings Call Transcript - Insider Monkey
Evolent Health (EVH) Shares Skyrocket, What You Need To Know - Finviz
EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious - Stocktwits
Truist cuts Evolent Health stock price target to $6 on 2026 outlook - Investing.com Australia
Evolent Health (EVH) Rating Maintained But Price Target Drastica - GuruFocus
Evolent Health (NYSE:EVH) Price Target Lowered to $4.00 at Needham & Company LLC - MarketBeat
RBC Capital Lowers Price Target for Evolent Health (EVH) by 40% - GuruFocus
Royal Bank Of Canada Cuts Evolent Health (NYSE:EVH) Price Target to $3.00 - MarketBeat
RBC Capital Adjusts Evolent Health PT to $3 From $5, Maintains Sector Perform Rating - marketscreener.com
KeyCorp Downgrades Evolent Health (NYSE:EVH) to Sector Weight - MarketBeat
BTIG Research Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price - MarketBeat
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
EVH: Keybanc Downgrades Evolent Health to Sector Weight | EVH St - GuruFocus
This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Evolent Health, Inc. SEC 10-K Report - TradingView
EVH: BTIG Lowers Price Target to $8, Maintains Buy Rating | EVH Stock News - GuruFocus
EVH | Evolent Health, Inc Class FinancialsIncome Statement - Quiver Quantitative
Evolent Health Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com Australia
Evolent Health Q4 Earnings Call Highlights - MarketBeat
Evolent Health Inc Stock (EVH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):